The main efficacy endpoint was alter from baseline MADRS rating. This limited-time period study identified that, compared to intranasal placebo plus oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant appreciably improved depressive signs and symptoms right after four weeks by a signify difference of four points ov